198 related articles for article (PubMed ID: 19732952)
1. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.
Valdez BC; Li Y; Murray D; Corn P; Champlin RE; Andersson BS
Leuk Res; 2010 Mar; 34(3):364-72. PubMed ID: 19732952
[TBL] [Abstract][Full Text] [Related]
2. Altered gene expression in busulfan-resistant human myeloid leukemia.
Valdez BC; Murray D; Ramdas L; de Lima M; Jones R; Kornblau S; Betancourt D; Li Y; Champlin RE; Andersson BS
Leuk Res; 2008 Nov; 32(11):1684-97. PubMed ID: 18339423
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.
Valdez BC; Tang X; Li Y; Murray D; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2018 Nov; 67():49-59.e1. PubMed ID: 30102945
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Song G; Valdez BC; Li Y; Dominguez JR; Corn P; Champlin RE; Andersson BS
Leuk Lymphoma; 2014 Jul; 55(7):1625-34. PubMed ID: 24144307
[TBL] [Abstract][Full Text] [Related]
5. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
Ishiguro M; Iida S; Uetake H; Morita S; Makino H; Kato K; Takagi Y; Enomoto M; Sugihara K
Ann Surg Oncol; 2007 May; 14(5):1752-62. PubMed ID: 17195906
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
[TBL] [Abstract][Full Text] [Related]
7. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status.
Xiong J; Epstein RJ
Mol Cancer Ther; 2009 Apr; 8(4):779-85. PubMed ID: 19372550
[TBL] [Abstract][Full Text] [Related]
9. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
[TBL] [Abstract][Full Text] [Related]
10. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
11. Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents.
Janotka Ľ; Messingerová L; Šimoničová K; Kavcová H; Elefantová K; Sulová Z; Breier A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669837
[TBL] [Abstract][Full Text] [Related]
12. Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.
Li K; Hu C; Mei C; Ren Z; Vera JC; Zhuang Z; Jin J; Tong H
J Transl Med; 2014 Jun; 12():167. PubMed ID: 24923330
[TBL] [Abstract][Full Text] [Related]
13. Retinoic acid receptor-β gene reexpression and biological activity in SHI-1 cells after combined treatment with 5-aza-2'-deoxycytidine and all-trans retinoic acid.
Xiang L; Wang R; Wei J; Qiu G; Cen J; Hu S; Xie X; Chen Z; Gu W
Acta Haematol; 2015; 133(3):279-86. PubMed ID: 25413479
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.
Qin T; Jelinek J; Si J; Shu J; Issa JP
Blood; 2009 Jan; 113(3):659-67. PubMed ID: 18931345
[TBL] [Abstract][Full Text] [Related]
15. Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells.
Pulukuri SM; Rao JS
Int J Oncol; 2005 Apr; 26(4):863-71. PubMed ID: 15753979
[TBL] [Abstract][Full Text] [Related]
16. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.
Steinhart L; Belz K; Fulda S
Cell Death Dis; 2013 Sep; 4(9):e802. PubMed ID: 24030154
[TBL] [Abstract][Full Text] [Related]
17. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
[TBL] [Abstract][Full Text] [Related]
18. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
19. Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2'-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis.
Liu W; Lee HW; Liu Y; Wang R; Rodgers GP
Blood; 2010 Dec; 116(23):4938-47. PubMed ID: 20724538
[TBL] [Abstract][Full Text] [Related]
20. 5-aza-2'-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells.
Gomyo Y; Sasaki J; Branch C; Roth JA; Mukhopadhyay T
Oncogene; 2004 Sep; 23(40):6779-87. PubMed ID: 15273730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
